Abstract:Ductal carcinoma (DCIS) constitutes an array of morphologically recognized intraductal neoplasms in the mammary ductal tree defined by an increased risk for subsequent invasive carcinomas at or near the site of biopsy detection. However, only 15-45% of untreated DCIS cases progress to invasive cancer, so understanding mechanisms that prevent progression is key to avoid overtreatment and provides a basis for alternative therapies and prevention. This study was designed to characterize the tumor microenvironment and molecular profile of high-risk DCIS that grew to a large size but remained as DCIS. All patients had DCIS lesions >5cm in size with at least one additional high-risk feature: young age (<45 years), high nuclear grade, hormone receptor negativity, HER2 positivity, the presence of comedonecrosis, or a palpable mass. The tumor immune microenvironment was characterized using multiplex immunofluorescence to identify immune cells and their spatial relationships within the ducts and stroma. Gene copy number analysis and whole exome DNA sequencing identified the mutational burden and driver mutations, and quantitative whole-transcriptome/gene expression analyses were performed. There was no association between the percent of the DCIS genome characterized by copy number variants (CNAs) and recurrence events (DCIS or invasive). Mutations, especially missense mutations, in the breast cancer driver genes and were common in this high-risk DCIS cohort (47% of evaluated lesions). Tumor infiltrating lymphocyte (TIL) density was higher in DCIS lesions with TP53 mutations (p=0.0079) compared to wildtype lesions, but not in lesions with mutations (p=0.44). Immune infiltrates were negatively associated with hormone receptor status and positively associated with HER2 expression. High levels of CD3+CD8-T cells were associated with good outcomes with respect to any subsequent recurrence (DCIS or invasive cancer), whereas high levels of CD3+Foxp3+ Treg cells were associated with poor outcomes. Spatial proximity analyses of immune cells and tumor cells demonstrated that close proximity of T cells with tumor cells was associated with good outcomes with respect to any recurrence as well as invasive recurrences. Interestingly, we found that myoepithelial continuity (distance between myoepithelial cells surrounding the involved ducts) was significantly lower in DCIS lesions compared to normal tissue (p=0.0002) or to atypical ductal hyperplasia (p=0.011). Gene set enrichment analysis identified several immune pathways associated with low myoepithelial continuity and a low myoepithelial continuity score was associated with better outcomes, suggesting that gaps in the myoepithelial layer may allow access/interactions between immune infiltrates and tumor cells. Our study demonstrates the immune microenvironment of DCIS, in particular the spatial proximity of tumor cells and T cells, and myoepithelial continuity are important determinants for progression of disease.

Risk Factors for Lymph Node Metastasis and the Impact of Adjuvant Chemotherapy on Ductal Carcinoma in Situ with Microinvasion: a Population-Based Study.

Incidence and Risk Factors of Lymph Node Metastasis in Breast Cancer Patients Without Preoperative Chemoradiotherapy and Neoadjuvant Therapy: Analysis of SEER Data.

Predictors for local invasive recurrence of ductal carcinoma in situ of the breast: a meta-analysis.

Clinicopathological Features of Breast Cancer Progression: from DCIS to Invasive Ductal Carcinoma

The Clinical Features and Management of Women with Ductal Carcinoma in Situ with Microinvasion: A Retrospective Cohort Study.

Characteristics, prognosis, risk factors, and management of recently diagnosed ductal carcinoma in situ with microinvasion

Risk Factors for Lymph Node Metastasis in Submucosally Invasive Colorectal Cancer

Biologic Behavior and Long-Term Outcomes of Breast Ductal Carcinoma in Situ with Microinvasion

Breast Ductal Carcinoma in Situ with Microinvasion: Clinicopathological Characteristics, Prognosis and Role of Surgery in Treatment

Meta‐analysis on axillary lymph node metastasis rate in ductal carcinoma in situ with microinvasion

[Surgical Treatment and Prognosis of Ductal Carcinoma in Situ: 526 Cases Analysis].

Clinicopathologic Study on Ductal Carcinoma in Situ with Microinvasion and Comedo-Necrosis of the Breast

Prognostic value of ductal carcinoma in situ component in invasive ductal carcinoma of the breast: a Surveillance, Epidemiology, and End Results database analysis.

Clinicopathological features and prognostic differences of ductal carcinoma in situ with ductal carcinoma in situ with microinvasion

Treatment Trends and Prognosis of Breast Ductal Carcinoma in Situ: a Single Center Analysis

Risk factors of microinvasion in breast ductal carcinoma in situ

Clinicopathological characteristics, treatments, and prognosis of breast ductal carcinoma in situ with microinvasion: A narrative review

Tumor microenvironmental determinants of high-risk DCIS progression

Long Term Prognosis of Ductal Carcinoma in Situ with Microinvasion: a Retrospective Cohort Study.

An insight into the invasion of breast ductal carcinoma in situ based on clinical, pathological and hematological data

Ductal Carcinoma in Situ Has Comparable Prognosis but Different Risk Factors with Ductal Carcinoma in Situ with Micro Invasion